What is the Immunohistochemistry Market Size?
The global immunohistochemistry market size is calculated at USD 3.49 billion in 2025 and is predicted to increase from USD 4.47 billion in 2026 to approximately USD 38.74 billion by 2035, expanding at a CAGR of 27.21% from 2026 to 2035. The demand for personalized medicines has increased, leading to driving the growth of the immunohistochemistry market. Rising prevalence of chronic diseases like cancer and infectious diseases is highly contributing to the market expansions. Growing adoption of digital pathology is expected to boost the market in the forecast period.
Immunohistochemistry Market Key Takeaways
- North America led the immunohistochemistry market in 2025 with revenue share of 39%.
- Asia Pacific anticipated to witness significant growth in the forecast period.
- By product, the antibodies segment dominated the market in 2025.
- By product, the kits segment is observed to grow at the fastest rate during the forecast period.
- By application, the diagnostics segment held the largest share of the market in 2025.
- By end-use, hospitals and diagnostics laboratories segment has contributed biggest share in the market in 2025.
- By end-use, the research institutes segment is seen to grow at a notable rate during the predicted timeframe.
Market Overview
The immunohistochemistry market is expanding due to more products being approved for use and the release of technologically sophisticated immunohistochemistry solutions for disease diagnosis. It is anticipated that the rising prevalence of chronic diseases will raise the demand for immunohistochemistry products, fueling market expansion.
The market for immunohistochemistry is expanding due to a growing emphasis on drug monitoring, better chances of detecting various diseases, technological advancements, and increased public awareness of new diagnostics equipment. The market for immunohistochemistry is predicted to grow slowly due to the low specificity of IHC techniques and their high setup costs. A cancerous growth must be accurately and promptly diagnosed to effectively manage a disease.
However, some chronic diseases cannot be accurately diagnosed using IHC techniques, which may prevent widespread use. Immunohistochemistry market expansion is constrained by the high setup cost of IHC equipment, a significant burden on diagnostic laboratories and hospitals in developing economies.
Additionally, extensive uses of immunohistochemistry in development and drug discovery activities are anticipated to spur revenue growth throughout the forecast period. And whole-slide imaging and Digital image analysis provide accurate and impartial assessments. Image analysis is therefore applicable to various drug discovery processes, such as target validation, biomarkers expression studies, patient stratification, drug repositioning, and efficacy of drugs and safety studies.
Artificial Intelligence: The Next Growth Catalyst in Immunohistochemistry
The integration of AI in research and developments has shown significant influence; the prevalence of chronic disease has witnessed AI as the spectacular helper in research and development of the novel therapies and drugs. Immunohistochemistry is nonexceptional in this. AI is benefiting the immunohistochemistry market by improving personalized medicine developments. The adoption of deep learning and machine learning has made it easier to study and understand the pathology, which further helps to develop precision medicines and targeted therapies.
Artificial Intelligence (AI) delivering spectacular work in diagnostic identification, identifying potential patients and their needs, risk management, as well as production areas. AI-enabled equipment, like automated the immunohistochemistry-staining process, immunohistochemistry-stained tissue sections, and samples for IHC analysis, making it much easier for developments of the immunohistochemistry test. With the integration of AI, the market is expected to witness more growth areas for research and developments in the upcoming years.
Immunohistochemistry Market Growth Factors
- Clinical pathology has seen a rise in the use of immunohistochemistry protocols, particularly in the fields of hematopathology, neuropathology and oncologic pathology.
- The immunohistochemistry method has significantly influenced cancer diagnostics. Therefore, the rising incidence of cancer is anticipated to boost the need for immunohistochemistry and fuel market expansion.
- The rising need for personalized medicines is also driving the adoption of immunohistochemistry to enhance tailored treatment approaches.
- The rapidly expanding applications in research and diagnostics for identifying novel biomarkers, studying tumor biology, neurological disorders, and Alzheimer's disease and Parkinson's disease are highly contributing to the major adoption rate of the immunohistochemistry system.
- The adoption of advanced technologies like automation, digital pathology, and staining techniques to improve efficiency and accuracy in immunohistochemistry testing is helping to develop cutting-edge and more effective treatment solutions, leading to further expansion of the market.
- The growing aging population and rising government investments in healthcare expenditure are also influencing the market growth.
Market Outlook
- Market Growth Overview: The immunohistochemistry market is expected to grow significantly between 2025 and 2034, driven by the rising prevalence of various cancers worldwide, emphasis on personalized medicine, and advancement in digital pathology and AI.
- Sustainability Trends: Sustainability trends involve miniaturization and resource optimization, transition to less toxic reagents, digital pathology for waste reduction, and eco-friendly packaging & lifecycle assessments.
- Major Investors: Major investors in the market include Roche Diagnostics, Danaher, Agilent Technologies, Thermo Fisher Scientific, OrbiMed Advisors, and ARCH Venture Partners.
- Startup Economy:The startup economy is focused on AI and digital pathology, multiplexing and spatial biology, and strategic acquisition targets.
Market Scope
| Report Coverage | Details |
| Market Size in 2025 | USD 3.49 Billion |
| Market Size in 2026 | USD 4.47 Billion |
| Market Size by 2035 | USD 38.74 Billion |
| Growth Rate from 2026 to 2035 | CAGR of 27.21% |
| Largest Market | North America |
| Base Year | 2025 |
| Forecast Period | 2026 to 2035 |
| Segments Covered | By Services, By Molecule and By Mode |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America and Middle East & Africa |
Market Dynamics
Drivers
The rise in the number of people with chronic diseases.
The rise of the elderly and the rising incidence of cancer are driving factors in the immunohistochemistry market. The IHC market is expected to expand due to additional factors like rising healthcare spending and improved healthcare infrastructure, which will eventually lead to more hospitals and diagnostic labs opening every day.
The market's growth rate is also boosted by using technologically developed immunohistochemistry solutions and expanding drug discovery and development activities.
The global immunohistochemistry market is expected to grow due to increasing product approvals and the emergence of technologically sophisticated immunohistochemistry remedies for disease diagnosis. Additionally, the participation of key players in developing IHC methods through partnerships with pharmaceutical drug companies to create and deliver IHC diagnostic solutions for their immunotherapies presents growth offers for the market players operating in the IHC market. Additionally, it is anticipated that increasing public awareness of chronic diseases will increase the need for immunohistochemistry products, eventually leading to growth in the IHC market.
The market's growth rate is also anticipated to be supported by the use of IHC in detecting several neurodegenerative disorders caused by numerous factors, including cannabidiol use and cigarette smoking.
Restraint
High level of consolidation
The expiration of antibody patents is a severe issue for the global market. The patent protection for some primary antibodies made and marketed by Merck (Germany) and F. Hoffmann-La Roche AG (Switzerland) is about to expire. As a result, such market participants' total revenue and profitability are declining.
Participants in the market must also deal with issues like heightened price pressure from governments around the world and reduced R&D output. To overcome these challenges, major market players are acquiring smaller and mid-sized competitors with innovative products. This provides a set of economic and distribution platforms for these goods to enter new international markets.
Opportunity
Rise in the demand for personalized medicine.
The rising need for companion diagnostics is contributing to increasing further the adoption of immunohistochemistry. Companion diagnostics are essential for the development of target therapies as they help to identify the patients who need relevant treatments. The advanced technologies like next-generation sequencing and artificial intelligence comply with personalized medicines by helping to identify patients and analyzing genetic mutations. With the rising incidence of chronic disease, the need for targeted and precision treatment options, ongoing research in genes and biomarkers, and the integration of advanced technologies, the research and development of personalized medicines are likely to improve in upcoming years, which will play a favorable role in the IMMUNOHISTOCHEMISTRY market growth.
Segment Insights
Product Insights
Due to the crucial role that antibodies play in drug testing and disease diagnosis; the antibodies market was dominated in 2025. In terms of utilisation, monoclonal antibodies and related products such as antibody fragments, Fc-fusion, and antibody-drug conjugates have taken the lead. The antibodies are used in various fields, including hematopathology, neuropathology, and pathology. The kits segment is expected to grow at the fastest CAGR during the forecast period.
The primary antibodies have the highest utilization rate in various research for chronic diseases like cancer, neurologic disorders, and infectious disease diagnosis due to their sensitivity and specificity in identifying biomarkers. Additionally, the secondary antibody uses are rising in multiplex staining IMMUNOHISTOCHEMISTRY applications, making the segment more popular in the market. The ability of recombinant antibodies to enhance consistency and reproducibility is also playing a crucial role in the segment's growth. With ongoing research and developments, the segment is expected to continue leading the market.
On the other hand, the Kits segments are expected to witness significant growth in the forecast period. Due to the convenience of using kits and their simplicity in development and research for educational and biotechnological procedures. Additionally, the sorted kits, which can be utilized without the inconvenience of measuring precise specific antibody stains for tissues, can save a ton of time and aid in preventing human errors during the procedure, fueling demand for the market. Moreover, several major companies are now offering kits and assays as immunohistochemistry R&D increases, driving the segment growth.
Due to the convenience of using kits and their simplicity in development and research for educational and biotechnological procedures, the IHC kits segment is also anticipated to experience severe expansion during the forecast period.
Additionally, the sorted kits, which can be utilized without the inconvenience of measuring precise specific antibodies stains for tissues, can save a tonne of time and aid in preventing human errors during the procedure, fueling demand for the market. Moreover, several major companies are now offering kits and assays as immunohistochemistry R&D increases, driving the segment growth.
Application Insights
The diagnostics segment dominated the global immunohistochemistry market. The increasing incidence and prevalence of cancer primarily drive the segment's growth. The application of immunohistochemistry in cancer diagnosis to detect biomarkers and tumor types is the major reason behind its rapid adoption in cancer diagnosis. Additionally, the increased prevalence of chronic and rare diseases is seeking personalized medicines, where immunohistochemistry helps to identify potential patients to apply the treatment as well as identify biomarkers and targeted therapies.
The majority of infectious diseases and the favourable reimbursement environment for immunohistochemistry tests are additional factors driving the segment's market share growth. Numerous chronic conditions, including autoimmune diseases, cancer, infectious diseases, cardiovascular diseases, diabetes mellitus, and nephrological diseases, can be diagnosed using immunohistochemistry tests. Moreover, it is anticipated that the increasing incidence of chronic diseases will continue drive the diagnostics segment.
Numerous chronic conditions, including autoimmune diseases, cancer, infectious diseases, cardiovascular diseases, diabetes mellitus, and nephrological diseases, can be diagnosed using immunohistochemistry tests. Moreover, it is anticipated that the increasing incidence of chronic diseases will drive the diagnostics market.
The increasing incidence and prevalence of cancer primarily drive the segment's growth. The majority of infectious diseases and the favourable reimbursement environment for IHC tests are additional factors driving the segment's market share growth.
End Use Insights
The hospitals and diagnostics laboratories segment accounted for the largest share of the global immunohistochemistry market in 2025. This expansion was anticipated due to the significant number of immunohistochemistry tests conducted in medical facilities. Moreover, the demand for hospitals with cutting-edge institutions has risen due to the healthcare sector's changes. The rise in people embracing technological advancements like digital pathology and automated sample preparation, which have significantly increased value, the segment is projected to witness more growth. Another major factor driving growth of the segment is increased disease diagnosis in the hospitals due to the increase in the incidence of chronic diseases.
However, the research institutes segment is anticipated to post a profitable CAGR during the forecast period due to the technique's numerous benefits over staining methods typically used in pharmaceutical development and research. For instance, Cell Signalling Technology offers a human-specific VISTA rabbit monoclonal antibody authorised by immunohistochemistry for biomedical research. The widespread use of immunohistochemistry methods in drug testing by research institutes can also be credited with the growth. The method enables the evaluation of biomarker distribution and localization and the expression of various proteins in various biological tissue sections, which is carried out in research settings. Research institutions use immunohistochemistry techniques to evaluate drug efficacy tests during drug development, that's leading the segment to grow further in the market.
“The Ziihera was previously received Breakthrough Therapy Designation from the FDA, and now it has received approval for this indication. It is an advanced modification and offers the first and only dual HER2-targeted bispecific antibody and chemotherapy-free treatment for patients living with BTC.”
Regional Insights
U.S. Immunohistochemistry Market Size and Growth 2026 to 2035
The U.S. immunohistochemistry market size is exhibited at USD 952.77 million in 2025 and is projected to be worth around USD 10,814.14 million by 2035, growing at a CAGR of 27.50% from 2026 to 2035.
North America led the immunohistochemistry market in 2025 with revenue share of 39%. Due to advancements in commercialization AND biotech. The increasing use of this immunohistochemistry equipment in diagnostic facilities and laboratories has contributed to the North American region's dominance. Additionally, the adoption of automated devices is increased by favorable reimbursement policies in nations including the United States and Canada, which supports the expansion of the immunohistochemistry market in the North American region.
U.S. Immunohistochemistry Market Trend
The United States leads the regional market due to increased prevalence of chronic diseases like cancer in the country. Rising obesity and changing lifestyles are impacting the country's market expansion. Moreover, ongoing technology advancements in molecular biology and pathology fields are unclosing doors for immunohistochemistry utilizations and requirements. Factors like an aging population, rising government initiatives in research & developments, and the presence of favorable pharmaceutical companies and well-established healthcare are significantly driving immunohistochemistry market growth in the United States.
- In December 2024, the Food and Drug Administration approved durvalumab of Imfinzi, AstraZeneca, for utilization in adults with limited-stage small cell lung cancer (LS-SCLC) if their disease hasn't increased by following concurrent platinum-based chemotherapy and radiation therapy.
Asia-Pacific region's immunohistochemistry market is anticipated to experience the fastest CAGR growth during forecasting. The economic growth development of nations like India, China, South Korea, and Singapore is blamed for the rapid expansion of the immunohistochemistry market in the Asia-Pacific region. Aside from these, the high rate of chronic diseases and the rapid ageing of the population are other factors driving the growth of the Asia-Pacific Immunohistochemistry Industry.
Japan Immunohistochemistry Market Trend
Japan is dominating the regional market due to rising government initiatives to reduce the disease burden in the country. Rising prevalence of cancer is the major factor driving growth of the market in Japan. China is the second largest leader of the market in Asia. This growth is anticipated due to rising investments in R&D, an aging population, and expanding advanced healthcare expenditures.
How did Europe Experience Notable Growth in the Immunohistochemistry Market?
Europe's high and rising cancer burden necessitates accurate and rapid diagnostic tools. This demand is further amplified by substantial government funding and a strong emphasis on personalized medicine, where IHC is crucial for identifying specific biomarkers. The region benefits from stringent quality assurance standards that favor advanced, automated platforms from major players. Furthermore, the rapid adoption of digital pathology systems integrated with AI software is enhancing diagnostic efficiency and accuracy.
Germany Immunohistochemistry Market Trend
Germany's aging demographic and a high cancer burden necessitate precise diagnostic strategies. The market is defined by a rapid shift toward digital pathology and AI integration, significantly enhancing diagnostic throughput and accuracy in clinical settings. As a European leader in personalized medicine, Germany increasingly utilizes IHC for companion diagnostics to guide targeted therapies. This advancement is supported by a powerful R&D ecosystem and stringent regulatory standards enforced by BfArM, ensuring high levels of standardization.
Value Chain Analysis of the Immunohistochemistry Market
Antibody and Reagent Development: This initial stage focuses on the R&D and production of primary and secondary antibodies, detection kits, and specialized reagents.
- Key Players: Abcam plc, Cell Signaling Technology, Agilent Technologies, and Merck KGaA.
Instrument Manufacturing and Automation: This stage involves the engineering of automated slide stainers, tissue processors, and high-resolution digital scanners.
- Key Players: Roche Diagnostics (Ventana), Danaher (Leica Biosystems), Thermo Fisher Scientific, and Sakura Finetek.
Digital Pathology and AI Integration: This rapidly growing stage involves the development of image analysis software and AI algorithms that quantify biomarker expression.
- Key Players: Philips Healthcare, Aiforia Technologies, PathAI, and Indica Labs.
Distribution and Laboratory Supply: Finished products and instruments are moved through specialized medical distribution networks to reach hospitals, diagnostic centers, and research institutes.
- Key Players: VWR (Avantor), Cardinal Health, McKesson Corporation, and Fisher Scientific.
Diagnostic Consultation and Clinical Application: The final stage is where pathologists interpret the IHC slides, often aided by digital tools, to provide a final diagnosis and treatment recommendation.
- Key Players: Quest Diagnostics, LabCorp, NeoGenomics Laboratories, and major University Medical Centers.
Immunohistochemistry Market Companies
- F. Hoffmann-La Roche Ltd.: Roche is a dominant leader providing fully automated tissue staining platforms, such as the BenchMark series, alongside a vast menu of high-quality companion diagnostic assays.
- Abcam plc. (Discovery Life Sciences)Abcam is a primary provider of high-affinity recombinant monoclonal antibodies (RabMAb) specifically validated for IHC applications. They contribute to the market by offering researchers and clinicians highly reproducible tools for detecting emerging and rare biomarkers.
- Thermo Fisher Scientific Inc.: This company offers an end-to-end IHC portfolio including tissue processors, high-sensitivity detection kits, and specialized antibodies for research and clinical use. They contribute by leveraging their massive global distribution network to make automated pathology solutions accessible to labs of all sizes.
- Merck KGaA: Through its Life Science business, Merck provides a critical array of high-quality reagents, specialized primary antibodies, and innovative staining solutions.
- Agilent Technologies, Inc.: Agilent's Dako brand is a cornerstone of the IHC market, specializing in standardized diagnostic kits and the widely used Autostainer and Omnis platforms. They contribute significantly through their leadership in companion diagnostics, particularly for HER2 and PD-L1 markers in oncology.
- Perkinelmer, Inc. (Revvity): Now operating as Revvity, the company provides advanced multispectral imaging and automated staining solutions for spatial phenotyping. They contribute by enabling high-throughput multiplex IHC, which allows researchers to study complex cellular interactions within the tumor microenvironment.
- Cell Signaling Technology, Inc.(CST): CST is renowned for its high-performance, rigorously validated antibodies that target specific signaling pathways and post-translational modifications. They contribute by ensuring that clinical pathologists have access to extremely specific tools for identifying active disease drivers in tissue samples.
- Danaher Corporation (Leica Biosystems): Through Leica Biosystems, Danaher offers the BOND series of automated stainers and Aperio digital pathology scanners, providing a seamless "Vision-to-Diagnosis" workflow.
- Bio-Rad Laboratories, Inc.: Bio-Rad provides a diverse range of antibodies and reagents used in specialized IHC research, with a focus on high-quality controls and secondary detection systems.
- Bio SB: This company focuses on the development of high-quality, cost-effective IHC antibodies and detection systems for clinical and research laboratories.
Latest Announcements by Industry Leaders
- In August 2024, Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus, talked about companies' new program launching towards using algorithms to surface patients.
“The company's new demonstration shows how the practical application of AI is likely to provide a positive influence on everyday clinical care by satisfying the needs of patients, as treatment choices have become majorly complex.”
- In november 2024, Rob Iannone, M.D., M.S.C.E., executive vice president, global head of research and development, and chief medical officer of Jazz Pharmaceuticals, statement on FDA approvale to zanidatamab-hrii (Ziihera);
Recent Developments
- In May 2024, AstraZeneca India received FDA approval for trastuzumab deruxtecan, called T-DXd, for patients with any advanced solid cancer if their tumors produce high levels of the protein HER2, or HER2-positive.
- In August 2024, Tempus AI, Inc. introduced its new algorithm that runs as part of xR, the company's RNA sequencing assay, which helps surface patients who are likely to get advantages from on-guideline immunohistochemistry (IHC ) testing.
- In November 2024, Jazz Pharmaceuticals, Inc., received the Food and Drug Administration's granted accelerated approval to zanidatamab-hrii, a bispecific HER2-directed antibody, for previously treated, unresectable, or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test.
Segments Covered in the Report
By Product
- Antibodies
- Primary Antibodies
- Secondary Antibodies
- Equipment
- Tissue Microarrays
- Slide Staining System
- Tissue Processing Systems
- Slide Scanners
- Others
- Reagents
- Histological stains
- Chromogenic Substrates
- Diluents
- Blocking Sera and Reagents
- Fixation Reagents
- Organic Solvents
- Stabilizers
- Proteolytic Enzymes
- Kits
- IHC Kits for Animal Tissue
- IHC Kits for Human Tissue
By Application
- Diagnostics
- Cancer
- Diabetes Mellitus
- Cardiovascular Diseases
- Infectious Diseases
- Autoimmune Diseases
- Nephrological Diseases
- Research Applications
- Drug Development and Testing
- Others
- Forensic applications
By End-Use
- Research Institutes
- Hospitals & Diagnostic Laboratories
- Others
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- The Middle East and Africa
For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at sales@precedenceresearch.com
Frequently Asked Questions
Ask For Sample
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
sales@precedenceresearch.com
+1 804-441-9344